The Radiopharmaceuticals Market size was estimated at USD 4.85 billion in 2022 and expected to reach USD 5.15 billion in 2023, at a CAGR 6.45% to reach USD 8.00 billion by 2030.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Radiopharmaceuticals Market.

  • Based on Type, market is studied across Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine. The Diagnostic Nuclear Medicine is further studied across Pet Radiopharmaceuticals and Spect Radiopharmaceuticals. The Pet Radiopharmaceuticals is further studied across F-18 and Ru-82. The Spect Radiopharmaceuticals is further studied across Ga-67, I-123, Tc-99m, and Tl-201. The Therapeutic Nuclear Medicine is further studied across Alpha Emitters, Beta Emitters, and Brachytherapy Isotopes. The Beta Emitters is further studied across I-131, Lu-177, Re-186, Sm-153, and Y-90. The Brachytherapy Isotopes is further studied across Cs-131, I-125, Ir-192, and Pd-103. The Therapeutic Nuclear Medicine commanded largest market share of 59.95% in 2022, followed by Diagnostic Nuclear Medicine.

  • Based on Procedural Volume, market is studied across Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures is further studied across Pet Radiopharmaceutical Procedure and Spect Radiopharmaceuticals Procedure. The Therapeutic Procedures is further studied across Alpha Emitter Procedure, Beta Emitters Procedure, and Brachytherapy Isotopes Procedure. The Therapeutic Procedures commanded largest market share of 62.54% in 2022, followed by Diagnostic Procedures.

  • Based on Application, market is studied across Diagnostic Applications and Therapeutic Applications. The Diagnostic Applications is further studied across Pet Applications and Spect Applications. The Pet Applications is further studied across Cardiology Indication, Neurology Indication, and Oncology Indication. The Spect Applications is further studied across Cardiology, Lymphoma, Neurology, and Thyroid. The Therapeutic Applications is further studied across Bone Metastasis, Endocrine Tumors, Lymphoma Therapeutic, and Thyroid Therapeutic. The Therapeutic Applications commanded largest market share of 58.18% in 2022, followed by Diagnostic Applications.

  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 35.14% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Radiopharmaceuticals Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Radiopharmaceuticals Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Radiopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Alliance Holdings Medical Limited, Bayer AG, Bracco Group, BWXT Medical Ltd., Cardinal Health, Inc., Clarity Pharmaceuticals, Curium Pharma, Eckert & Ziegler Group, Eczacibasi-Monrol Nuclear Products Co., Fusion Pharmaceuticals Inc., GE Healthcare, Global Medical Solutions, Institute of Isotopes Co. Ltd., International Isotopes, Inc., IsoTherapeutics Group, LLC, Isotopia Molecular Imaging Ltd., Jubilant Pharma Holdings Inc., Lantheus Medical Imaging, Inc., Mallinckrodt PLC, Medi-Radiopharma, Navidea Biopharmaceuticals, Inc., Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., SHINE Medical Technologies, Siemens Healthineers AG, Sinotau Pharmaceutical Group, Sotera Health Holdings, LLC, and State Atomic Energy Corporation Rosatom.

The report offers valuable insights on the following aspects:

  1. Market Penetration: It provides comprehensive information about key players’ market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast for the Radiopharmaceuticals Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Radiopharmaceuticals Market?
  3. What is the competitive strategic window for identifying opportunities in the Radiopharmaceuticals Market?
  4. What are the latest technology trends and regulatory frameworks in the Radiopharmaceuticals Market?
  5. What is the market share of the leading vendors in the Radiopharmaceuticals Market?
  6. Which modes and strategic moves are suitable for entering the Radiopharmaceuticals Market?